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This article analyses the impact of MERCOSUR on the
pharmaceutical sector. It concludes, among other things, that
the sector suffered strong impacts, both static and dynamic,
as a result of the integration process. From the static point
of view, it may be observed that integration has given rise to
a marked increase in intrazonal trade, which reflects the
existence of a substantial trade creation process in
MERCOSUR. From the dynamic point of view, the
outstanding aspect is the increasing interest in regaining a
place in the markets of Argentina and Brazil shown by
transnational corporations since the integration process. This
process, together with the changes in the regulations on
medical patents, has given rise to big changes in the strategies
and positions of laboratories of domestic origin.
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I
Introduction
Not only is the evaluation of the benefits of integration
processes a difficult task, as also is the appraisal of their
costs, but moreover there is no consensus as to how to
carry it out.
Most economic studies consider that the static
effects in terms of creation or diversion of trade are the
fundamental variable for such evaluation. However,
these effects leave out the potential dynamic benefits
that may be derived from the integration process, such
as the development of technological change, of learning
processes, of production specialization, etc. These
dynamic effects are those which provide the most
convincing arguments in favour of integration
processes, as compared with arguments in favour of
the unilateral opening of the economy. The problem
arises, however, with regard to the difficulties in
measuring these benefits, since they cannot be
determined solely on the basis of analyses of growth
rates or of the behaviour of regional trade flows.
These difficulties point to the need for methods of
working at a more disaggregated level, which would
make it possible to identify processes that could not be
detected at the global level. In order to do this, we
analysed the changes which took place within each
sector of production,1 in order to determine the effects
on the levels and forms of organization of production,
business strategies, levels of technological modernity,
the regional dynamics of the sector, etc. This type of
analysis calls, as far as possible, for the isolation of the
effects of integration processes from the effects of the
other changes which are taking place in the economies
of the area (processes of greater openness, privatization,
etc.). This provides us with suitable elements for
determining what kind of national or community
policies could be applied in the future in order to make
MERCOSUR a dynamic element in production
development.
In line with this methodological approach, in the
present article we will analyse the impact of MERCOSUR
on the pharmaceutical sector.2 This is a very interesting
sector from the point of view of analysing the effects
of regional integration because of its strategic
importance, the fact that it has registered growing intra-
zonal and extra-zonal trade flows, and the profound
changes it is undergoing both at the world level and
within the countries making up the MERCOSUR zone.
Thus, the cost and way of financing the population’s
access to medicines is and always has been a source of
considerable concern for governments, while the level
of technological innovation and dynamic efficiency
attained by the sector can be an important factor in its
insertion in regional and world markets.
Anticipating the findings set forth later in this
article, it may be noted that the sector has suffered
strong static and dynamic impacts as a result of the
integration process. Firstly, the integration of the
MERCOSUR area has given rise to a marked increase in
intra-area trade: as imports from outside the area have
also increased but production levels have grown much
less, it may be inferred that a considerable trade creation
process has taken place in MERCOSUR. The dynamic
impacts are due to different causes, including the
growing interest displayed by transnational
corporations, in the light of the integration process, in
strengthening their positions in the Argentine and
Brazilian markets because of the greater possibilities
of expanding intra-company trade.
The pharmaceutical sector displays an increasing
degree of internationalization, and at the world level it
is dominated by a handful of companies whose efforts
in the field of competition are based on the ongoing
introduction of new products through scientific and
technological research as well as on heavy expenditure
on marketing and publicity for their existing products.
Indeed, within the region the proprietary ethical drugs
1
 This is because each sector is affected very differently, either
because of its previous situation as regards competitiveness, the
possibilities of taking advantage of latent demand in other markets,
or the special ways in which differences between the levels of
regulation of partner countries affect the sector.
2
 The pharmaceutical sector forms part of a chain of production
which begins with the discovery of a molecule or active principle
and culminates in the industrial production of pharmaceuticals.
These two stages make up the “pharmaceutical industry”, which is
part of what is generally known as the “fine chemicals industry”.
The pharmaceutical industry proper, which will be analysed in this
article, comprises the production and marketing of pharmaceutical
specialities or medicines.
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segment is clearly dominated by the big transnational
corporations.3 These corporations act very dynamically
as regards the location of their plants and their national
specialization patterns.
In the case of generic products, capacity for
innovation and marketing expenditure play only a
secondary role: price competition is the key factor, and
this makes it necessary to pay more attention to process
technologies and economies of scale.
In most of the countries, in addition to the
transnationals there are also local-capital firms which
produce pharmaceutical specialities. These firms use
generic drugs, which cost less than the corresponding
patented drugs, as their inputs, and they carry out hardly
any research activities, although they do spend a certain
amount on product development. They compete with
each other and with the subsidiaries of the big
transnationals on the basis of price and marketing costs,
and the brand name and corporate image are
fundamental elements of competition. In the case of
ethical products, the marketing effort is aimed at the
medical profession, because it is the doctors who
prescribe one or another specific medicine for their
patients. In the case of products which are sold freely
to the public, the competition is based on the brand
name, promoted through intensive mass publicity.
The intrinsic nature of the products of this industry,
which are intended for public health purposes, as well
as the importance of scientific and technological
research activities, make this a highly regulated sector.4
First of all, we will look at the asymmetries in
regulations between Argentina and Brazil (section II)
and the performance of the sector in the individual
MERCOSUR countries (section III), concluding with an
appraisal of the static and dynamic effects of the
integration process, as identified from statistical
analysis and field studies in Brazil, Uruguay and
Argentina5 (section IV).
II
Policy asymmetries in MERCOSUR
The policy asymmetries in MERCOSUR may be observed
in two fields: in the global policies for the promotion
of investment, production, innovation and exports, and
in the differences in the regulatory framework
specificically affecting the pharmaceutical sector.
During the import substitution industrialization
phase, the MERCOSUR countries, and especially
Argentina and Brazil, developed a wide range of
promotion instruments which combined high rates of
trade protection with special investment promotion
regimes and, later, export promotion measures. Towards
the end of the 1980s, the MERCOSUR countries embarked
on a reform process aimed at economic liberalization
and at the elimination of the State promotion and
regulation machinery, including the pharmaceutical
sector.
In the case of Brazil, however, various investment
incentives adopted by the federal and state governments
remain in force. The latter enjoy fiscal powers which
are even broader than those of the provinces in
Argentina, so that they have considerable possibilities
for granting fiscal incentives in the form of the reduction
or financing of the goods and services turnover tax in
order to attract new investments. State incentives are
often also granted for labour training and development
of infrastructure.
3
 Medicines for human consumption are divided into ethical and
non-ethical drugs. The first group comprises all those medicines
which are sold exclusively on a doctor’s prescription, and they may
be further divided into generic and proprietary medicines. Generic
medicines are those whose patents have run out, so that they can
now be freely manufactured. Proprietary medicines, in contrast (in
countries which accept the corresponding rules), can only be
manufactured by the patent-holders or under licence from the latter,
so they generally cost more. Non-ethical drugs are those which
can be acquired without a doctor’s prescription.
4
 The provisions on patents adopted in 1994 in the agreements on
Trade-Related Intellectual Property aspects of the General
Agreement on Tariffs and Trade (GATT) oblige countries, once they
come into force, to provide patent protection for pharmaceutical
products and the corresponding production processes. Although
the developing countries were given a five-year period of grace,
these agreements are having a profound impact on countries which
did not recognize patents in this respect and had managed to develop
industries based on imitative development efforts by local firms
(such as India and Argentina).
5
 The field studies consisted of standardized interviews with
representatives of about 15 firms in each of the countries and the
main trade associations of the sector.
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In Uruguay, the structural reforms have been more
gradual (there has been practically no privatization of
public enterprises), although the process of unilateral
trade openness did advance during the 1990s (Laens,
Lorenzo and Osimani, 1993; Torrello and Noya, 1992).
Since the early 1990s, however, new policy
instruments have been appearing which are designed
to promote technological development and business
restructuring, such as the Argentine Technological Fund
(FONTAR), aimed at the promotion of technological
innovation, and a variety of export incentives, such as
temporary admission and export drawbacks, which have
been used by most of the Argentine laboratories
interviewed.
As part of the general tendencies to rationalize and
reduce public intervention in industrial policy matters,
substantial changes were made in all the MERCOSUR
countries in the policies on regulation of the
pharmaceutical sector, which was subject up to the late
1980s to severe restrictions in terms of price formation
mechanisms and external suppliers. In the 1990s, in
both Argentina and Brazil, a number of deregulatory
measures were taken, beginning with the elimination
of maximum price controls, although there are still
substantial differences in regulations between the two
countries in two fields: the registration of medicines
and patent law.
With regard to the registration of medicines,
Argentina has eased the rules in this respect in order to
facilitate the importation of medicines as a means of
fomenting competition with local products. To this end,
in 1992 it set up the special register for authorized
medicines.6 In Brazil, in contrast, the mechanism for
the registration of medicines is much more restrictive,
since it requires the submission of samples for analysis
and a number of tests considered necessary by the health
authorities. These requirements impose serious
limitations on Brazilian imports of medicines from the
MERCOSUR countries and oblige companies in those
countries to establish agreements with Brazilian firms
which have products that are already registered with
the health authorities (De Queiroz, 1993).
With regard to the new patent legislation, this does
not have retroactive effect in Argentina: i.e., it does not
affect products which circulated in that country or were
covered by patents granted in other countries prior to
1995 (when the new regulations came into effect).
Moreover, new inventions of pharmaceutical products
are not patentable in Argentina until five years after
the publication of the law (Challú and Lewis, 1996).
After that date, the patent-holders will enjoy a
monopoly of their use for 20 years, provided that they
are indeed effectively used, since when a patent is not
used, the authorities are empowered to grant
exploitation rights to third parties. “Exploitation” or
“use” is considered to be the proper distribution and
marketing of the product covered by the patent in
question, whether through domestic production or
importation.7
In Brazil, the patents law has been in force since it
officially came into effect (May 1996) and it likewise
provides that the use must be “effective”, but unlike
the Argentine law it considers that use or exploitation
can only mean supply of the domestic market through
the domestic manufacture of finished products. This
means that if a firm wants to enjoy monopoly rights to
use its invention, it must manufacture the product in
Brazil. This requirement for domestic production has
already given rise to an application for a panel by the
United States, that is to say, an application for the case
to be decided within the World Trade Organization
(WTO).8
These differences between Argentina and Brazil
with respect to patents law may turn out to be of decisive
importance in the strategies adopted by pharmaceutical
firms, encouraging them to operate plants in Brazil,
since supplying a product from that country can give a
patent-holder monopoly rights in both countries (as
Argentina considers importation equivalent to use),
6
 In that year, automatic registration was decreed for all medicinal
specialities already circulating in the country, as well as for those
which were authorized in the domestic markets of a number of
countries considered to be of “high levels of sanitary supervision”,
a list of which is given in annex I of the decree in question. At the
same time, a maximum deadline of 120 days was established for
the authorization and registration of products similar to those
already registered in the country, either for domestic production or
for importation from countries listed in annex II.
7
 Towards the beginning of 2000, when the payment of
pharmaceutical patents was to come into force in Argentina, there
was a heated debate in that country as to whether the requirement
of “exploitation” or “use” of patents should involve domestic
production of the medicine in question, as in Brazil.
8
 Brazil, in turn, has just denounced the fact that the United States
makes a similar stipulation for a number of medicines, and it
recently won a vote in the Human Rights Commission (by 53 votes
to 1) which condemned the abuse of patent rights by some
pharmaceutical companies. Furthermore, under international
pressure, a number of such companies have recently abandoned an
action against South Africa for the use of basic drugs needed to
treat AIDS. All this means that the discussion on patents law may
take a new turn in the future (Watal and Mathai, 1995).
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whereas if a firm sets up a factory in Argentina it may
be obliged to grant a licence to manufacture the product
in Brazil. Moreover, the difference between the dates
of entry into effect of the two laws (with regard to
pharmaceutical products) may operate in the same
direction during the transitional period in Argentina,
in the case of the establishment of plants to use
companies’ own inventions. In this case, production in
Brazil at least ensures monopoly rights in that country,
whereas production in Argentina does not ensure this
in either country.
Another aspect worthy of note is that in both
countries there have been attempts to promote sales
through generic medicines, but there is still a long way
to go in this respect. In Argentina, it was decreed that
lists of the trade names of medicines should be prepared,
grouped together according to their generic names, and
doctors were obliged to use the latter names when
writing prescriptions, but this obligation proved hard
to enforce, and in a later decree doctors were left free
to write prescriptions as they saw fit. In Brazil, it was
decreed in February 1999 that all medicines sold under
brand names must clearly show on their packages the
name of their active principles.9
Furthermore, within the process of harmonization
of rules which is taking place in MERCOSUR, progress
has been made in the rules on inspection of the quality
of medicines, good manufacturing practices for them,
inspection of manufacturing plants and guidelines
therefor, and the training of inspectors. This
harmonization process makes it possible to advance
towards mutual recognition of the government agencies
of both countries responsible for authorizing the sale
of medicinal specialities in the respective domestic
markets, and has also aided in the exchange and
upgrading of know-how.
III
Recent evolution of the
pharmaceutical sector in MERCOSUR
1. Structure and recent performance
The pharmaceutical sector of the different MERCOSUR
countries displays some common structural features.
Firstly, there is a clear division between
transnational and national laboratories. In Argentina and
Uruguay, the turnover of the sector is divided more or
less equally between the two types, but in Brazil the
ratio is 75% to 25% in favour of the transnationals.10
The differences in ownership are also reflected in
different types of microeconomic behaviour: the
national laboratories generally do not carry out
scientific and technological research and survive by
copying medicines developed abroad, whereas the
transnational laboratories apply in the local market the
innovations made in world-level research centres. In
both cases the active principles are mostly imported.
Secondly, although the pharmaceutical market as
a whole is not very concentrated (the ten main firms
account for no more than 40% of total sales in Argentina
and Brazil), within each therapeutic speciality the level
of concentration is markedly greater.11 Promotion
(largely through salesmen visiting doctors) and brand
names are the main forms of competition, with
competition on price only playing an important role in
direct sale to public health systems (hospitals, etc.).
There are considerable differences between the
various MERCOSUR countries as regards the size of
firms. Thus, in Brazil over 50% of the turnover is
accounted for by big laboratories with over 500
employees, whereas in Uruguay most of the firms are
small, and up to 1997 there was only one laboratory
with more than 100 employees.
The demand structure also seems to differ
significantly in the three countries studied. In Brazil,
this structure is made up of almost a thousand9 In order to further this process, the Brazilian Health Supervision
Agency was given 90 days to establish the criteria for determining
the therapeutic equivalence of generic medicines and the exceptions
to this rule when expressly requested by the prescribing physician.
10
 In the case of Uruguay, the category “national laboratories” also
includes those of a binational or multi-Latin American nature.
11
 In the case of Brazil, for example, the share of the leading
laboratory comes to 91% for the generic medicine paracetamol,
58% for amoxycillin, and 93% for dipirone.
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distributors and 46,000 pharmacies. The distributors
operate at the regional level, and only in recent years
have they begun to operate at the national level. In
Argentina, in contrast, the distribution of medicines is
concentrated in three big firms in which the most
important laboratories play an active part. These
distributors have also moved into the level of the retail
pharmacies, thus increasing still further the degree of
concentration.
The apparent production and consumption of
pharmaceutical products, measured in current dollars,
displays an upward long-term trend, especially in
Argentina and Brazil, as may be seen from table 1. In
1996 the output of the three countries studied amounted
to US$ 21 billion in current terms, of which Brazil
accounted for 82%, Argentina for 17% and Uruguay
for the remaining 1%.12
However, the increases in production levels in
current dollars reflect not only changes in physical
output but also in the real exchange rate and the price
levels of pharmaceutical products. If these increases
are measured at constant prices, the picture undergoes
a radical change: only the Brazilian pharmaceutical
industry registers an increase in the physical volume
of production during the 1990s. This growth took place
after the introduction of the Plano Real and amounted
to 23.6% between 1994 and 1998 (which is still a long
way from the 42% increase in output in constant dollars
registered over the same period). In the case of
Argentina, unit sales shrank by around 10% between
1991 and 1997, so that the whole of the increase in
production in current dollars was due to the big increase
in the average prices of the industry’s production
(Ministry of Economic Affairs of the Province of
Buenos Aires, 1997).
This indicates that, in spite of the tariff reduction
process which took place in the 1990s, the MERCOSUR
pharmaceutical industry registered a sharp recovery in
its relative prices during that decade.
2. Evolution of trade in pharmaceutical products
during the 1990s
a) Total exports and imports
MERCOSUR external trade in pharmaceutical products
grew strongly in the 1990s, with imports growing more
12
 It should be noted that the production figures for Brazil also
include the perfumery and toiletry sector, so that Brazil’s share in
the total MERCOSUR pharmaceutical market is somewhat
overestimated.
TABLE 1
Production and apparent consumption of pharmaceutical
products in Argentina, Brazil and Uruguay
(Millions of current dollars)
Argentina Brazil Uruguay
Year Production Trade Apparent Production Trade Apparent Production Trade Apparent
balance consumption balance consumption balance consumption
(exports- (exports- (exports-
imports) imports) imports)
1988 1 197 -29 1 226 ... ... ... ... ... ...
1989 927 -24 951 7 565 -62 7 606 ... ... ...
1990 1 441 -21 1 462 10 973 -157 11 276 ... ... ...
1991 2 087 -45 2 132 8 769 -159 9 090 146 -14 160
1992 2 468 -107 2 575 9 767 -117 10 009 147 -26 173
1993 3 005 -135 3 140 12 058 -176 12 476 185 -41 236
1994 3 427 -235 3 662 14 338 -339 14 993 183 -50 233
1995 3 396 -204 3 600 17 040 -406 17 964 193 -57 250
1996 3 423 -221 3 644 17 540 -701 18 575 201 -75 276
1997 3 606 -234 3 840 19 700 -1 170 20 905 ... ... ...
1998 ... ... ... 20 313 ... 21 643 ... ... ...
Source: Argentina:  on sales, Cámara Argentina de Especialidades Medicinales (CAEME); on external trade, Instituto Nacional de Estadísticas
y Censos (INDEC). Brazil: on production and apparent consumption, Fundação Comércio Exterior (FUNCEX) (production data include perfumery
and toiletry sector); on the trade balance, data prepared by the authors on the basis of data from the INTAL database. Uruguay: Uruguayan
report with data from the Instituto Nacional de Estadística (INE).
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than exports (tables 2 and 3).13 As a result, the trade
deficit of the pharmaceutical sector widened from
US$ 204.3 million in 1990 to US$ 1,022.1 million in
1996 (table 4).
Within this overall situation, the shares of the
different MERCOSUR countries are not in line with their
relative sizes both as regards exports and gross values
of production, as Argentina and Uruguay account for
relatively high proportions of total exports, whereas
Brazil’s share is relatively small for the country’s size.
In this sense, Argentina figures as the main exporter of
the area, with 53% of its exports in 1996, while Brazil
13
 It should be noted that the primary data are taken from
publications of the official statistical bodies of the countries. This
gives rise to problems of reliability and consistency of the external
trade figures. Thus, for example, exports FOB from Argentina to
Brazil in 1989 (as declared by Argentina) came to US$ 186,000,
whereas imports CIF by Brazil from Argentina in the same year (as
TABLE 2
MERCOSUR exports of pharmaceutical products
1990 1991 1992 1993 1994 1995 1996
Thousands of dollars
Argentina 21 569 44 556 48 258 73 656 91 357 131 303 179 058
Brazil 43 884 50 652 66 129 62 332 83 174 111 164 131 178
Uruguay 6 091 14 142 14 119 12 116 13 460 23 636 21 597
Paraguay 156 452 1 328 2 004 3 689 2 987 4 293
MERCOSUR 71 700 109 802 129 834 150 108 191 680 269 090 336 126
Percentages
Argentina 30 41 37 49 48 49 53
Brazil 61 46 51 42 43 41 39
Uruguay 8.5 13 11 8 7 9 6
Paraguay 0.5 0 1 1 2 1 1
MERCOSUR 100 100 100 100 100 100 100
Source: Prepared by the authors on the basis of data from the INTAL database.
TABLE 3
MERCOSUR imports of pharmaceutical products
1990 1991 1992 1993 1994 1995 1996
Thousands of dollars
Argentina 42 322 89 601 155 955 207 999 362 362 335 596 400 896
Brazil 200 903 209 423 183 126 238 692 422 086 517 319 832 378
Uruguay 21 310 27 397 36 676 43 460 54 740 66 659 79 763
Paraguay 11 499 18 962 23 545 29 038 50 954 38 913 45 184
MERCOSUR 276 034 345 383 399 302 519 189 854 142 958 487 1 358 221
Percentages
Argentina 15 26 39 40 38 35 30
Brazil 73 61 46 46 49 54 61
Uruguay 8 8 9 8 6 7 6
Paraguay 4 5 6 6 6 4 3
MERCOSUR 100 100 100 100 100 100 100
Source: Prepared by the authors on the basis of data from the INTAL database.
declared by Brazil) came to US$ 1.8 million, and Uruguay’s exports
FOB to Brazil in 1996 (as declared by Uruguay) came to US$ 10.1
million, whereas the CIF value declared by Brazil came to US$ 20
million. Generally speaking, there are big discrepancies between
the FOB and CIF values declared by trading partners in intrazonal
trade, and these differences are not always in the expected direction.
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is the main importer, with 61% of the area’s imports in
that year.
As regards the degree of trade openness of the
sector, it should be noted that the pharmaceutical
industry of the MERCOSUR countries has been and
continues to be aimed basically at the domestic market,
as witness the low export coefficients (table 5).
Nevertheless, in the 1990s exports grew faster than
output, especially in Argentina.
The coefficients of openness to imports are slightly
higher than the export coefficients, but even so (except
in the case of Uruguay) the import penetration of
pharmaceutical products continues to be relatively low.
If the supply of raw materials for the industry
(pharmaceutical chemicals) were taken into account,
however, those coefficients would be substantially
higher.
In the geographical pattern of external trade in
pharmaceutical products in MERCOSUR, there is a
marked difference between exports and imports.
Exports to the zone account for a growing share of the
total, as those destined for the rest of the world grow
substantially slower and are mostly to developing
countries, especially of Latin America (table 6).
Imports, in contrast (table 7), show that although
the share of MERCOSUR member countries has grown
in recent years, in 1996 imports from Brazil and
Argentina only came to 10% or 12% of the total,
indicating that the bulk of imports continue to come
from the developed countries (the United States and
Europe).
b) Index of revealed comparative advantages
In the 1990s the MERCOSUR countries were affected to
a greater or lesser extent by marked macroeconomic
fluctuations which had a heavy impact both on their
global trade balances and on those corresponding to
specific sectors of production. For this reason, in this
article we will use the index of revealed comparative
advantages14 (also called the index of contribution to
the total balance), as a way of separating within the
sectoral balances the effects of changes in the global
trade balances.
Table 8 shows that in the pharmaceutical sector
MERCOSUR has a revealed comparative disadvantage
with the rest of the world which grew more pronounced
during the 1990s. This means that the normalized trade
deficit of the sector (discounting the effect of global
trade deficits or surpluses) has increased in relation to
the total volume of trade of the area. It may be deduced
from this that there have been structural changes in the
TABLE 4
MERCOSUR trade balance for pharmaceutical products
(Thousands of dollars)
1990 1991 1992 1993 1994 1995 1996
Argentina -20 753 -45 045 -107 697 -134 343 -235 005 -204 293 -221 838
Brazil -157 019 -158 771 -116 997 -176 360 -338 912 -406 155 -701 200
Uruguay -15 219 -13 255 -22 557 -31 344 -41 280 -43 023 -58 166
Paraguay -11 343 -18 510 -22 217 -27 034 -47 265 -35 926 -40 891
MERCOSUR -204 334 -235 581 -269 468 -369 081 -662 462 -689 397 -1 022 095





1991 1 2 10
1992 1 2 10
1993 1 2 7
1994 1 3 7
1995 1 4 12
1996 1 5 11
1997 3 7 ...
Source: Data on production: country reports for Argentina, Brazil
and Uruguay. Data on trade: prepared by the authors on the basis
of data from the INTAL database, except for Brazil in 1997, which
was taken from the corresponding country report.
14
 The index of revealed comparative advantages is constructed by
deducting from the sectoral trade balance a theoretical value
representing the sector’s share in the global trade balance. This
share is expressed in thousandths of total trade, and its value may
vary between -500 and +500 (corresponding to complete
specialization). The formula for this indicator is: VCR = ((Xi-Mi)
– (Xi+Mi)/(X+M) * (X-M)) * 1000 / (X+M).
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pattern of trade which are not exclusively due to the
change in macroeconomic conditions that took place
in the 1990s.
This overall behaviour of the pharmaceutical sector
corresponds more or less closely to the individual cases
of the MERCOSUR countries. In all of them, exports and
imports expanded at a rapid rate and the sectoral trade
deficit and revealed comparative disadvantage have
tended to grow worse.
3. Intrazonal trade in MERCOSUR
As a result of the regional integration process, intrazonal
trade has grown even faster than trade outside the area.
Thus, during the period studied, intrazonal exports grew
by 1,110%, from US$ 14.6 million in 1990 to US$ 176.7
million in 1996 (tables 9 and 10).
In intrazonal exports, it may be seen that
Argentina’s leading position in exports is even more
TABLE 6
Destination of exports by Argentina, Brazil and Uruguay
(Percentages)
Destination/year 1990 1991 1992 1993 1994 1995 1996
Argentina MERCOSUR 44 41 48 49 56 53 61
Rest of world 56 59 52 51 44 47 39
Brazil MERCOSUR 8 14 20 22 27 37 41
Rest of world 92 86 80 78 73 63 59
Uruguay MERCOSUR 28 70 55 58 56 70 58
Rest of world 72 30    45 42 44 30 42
Source:  Prepared by the authors on the basis of data from the INTAL database.
TABLE 7
Origin of imports by Argentina, Brazil and Uruguay
(Percentages)
Destination/year 1990 1991 1992 1993 1994 1995 1996
Argentina MERCOSUR 1 4 6 6 5 12 12
Rest of world 99 96 94 94 95 88 88
Brazil MERCOSUR 1 5 6 5 6 8 10
Rest of world 99 95 94 95 94 92 90
Uruguay MERCOSUR 28 40 36 38 42 41 42
Rest of world 72 60 64 62 58 59 58
Source: Prepared by the authors on the basis of data from the INTAL database.
TABLE 8
Index of revealed comparative advantages in the MERCOSUR pharmaceutical sector
(Thousandths of total trade)
1990 1991 1992 1993 1994 1995 1996
Argentina -3.22 -3.44 -3.20 -3.36 -4.56 -5.23 -4.68
Brazil -3.99 -4.01 -3.28 -3.46 -4.93 -4.02 -6.42
Uruguay -5.71 -4.35 -5.35 -5.47 -6.88 -5.91 -7.31
Paraguay -4.68 -6.62 -7.65 -7.47 -7.72 -3.60 -4.61
MERCOSUR -3.99 -4.05 -3.83 -4.03 -5.36 -4.45 -5.90
Source: Prepared by the authors on the basis of data from the INTAL database.
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pronounced than in exports to the world as a whole
(indicating greater dependence by Argentina on the area
market). On the import side, it may be seen that Uruguay
and Paraguay have much greater relative weight (i.e.,
both of them purchase a relatively greater proportion
of their imports from other MERCOSUR countries).
This behaviour of the trade flows gives rise to an
intrazonal trade pattern in which Argentina increasingly
figures as the only country with a trade surplus, whereas
Uruguay, Paraguay and, since 1994, Brazil have deficits
(table 11).
The faster growth of intrazonal exports
compared with those to the rest of the world reflects
a general trend in the trade of MERCOSUR’s trading
partners. The zonal orientation index15 (table 12)
shows that, in the cases of Argentina and Brazil,
pharmaceutical exports register a zonal orientation
which is substantially greater than 1. In other words,
TABLE 9
Intra-MERCOSUR exports of pharmaceutical products
1990 1991 1992 1993 1994 1995 1996
Thousands of dollars
Argentina 9 553 18 138 23 025 36 170 50 836 69 056 108 584
Brazil 3 385 7 038 13 343 13 390 22 197 41 280 53 735
Uruguay 1 692 9 927 7 814 7 040 7 502 16 642 12 614
Paraguay 16 281 684 1 187 2 515 828 1 772
MERCOSUR 14 646 35 384 44 866 57 787 83 050 127 806 176 705
Percentages
Argentina 65 51 51 63 61 54 61
Brazil 23 20 30 23 27 32 30
Uruguay 12 28 17 12 9 13 7
Paraguay 0 1 2 2 3 1 1
MERCOSUR 100 100 100 100 100 100 100
Source: Prepared by the authors on the basis of data from the INTAL database.
TABLE 10
Intra-MERCOSUR imports of pharmaceutical products
1990 1991 1992 1993 1994 1995 1996
Thousands of dollars
Argentina 626 3 315 9 809 12 484 17 426 39 648 48 915
Brazil 2 310 9 582 10 244 12 313 24 227 42 765 79 435
Uruguay 6 056 10 882 13 207 16 586 22 793 27 176 33 659
Paraguay 6 460 10 099 12 370 16 870 19 434 22 554 29 169
MERCOSUR 15 452 33 878 45 630 58 253 83 880 132 143 191 178
Percentages
Argentina 4 10 21 21 21 30 26
Brazil 15 28 22 21 29 32 42
Uruguay 39 32 29 28 27 21 18
Paraguay 42 30 27 29 23 17 15
MERCOSUR 100 100 100 100 100 100 100
Source:  Prepared by the authors on the basis of data from the INTAL database.
15
 The zonal orientation index compares the relative importance of
the zonal market for the sector’s exports with its importance for
the country’s total exports. The indicator ranges from zero to
infinity. A value of 1 suggests that there is no zonal orientation.
The corresponding formula is:
IORi = Xij/Xi/Xj/X.
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the pharmaceutical exports of Argentina16 and Brazil
depend on intrazonal markets relatively more than
the total exports of each of those countries. In Brazil,
however, that zonal orientation displays an upward
trend during the decade, whereas in Argentina the
trend is downward.
TABLE 11
Intra-MERCOSUR trade balance for pharmaceutical products
(Thousands of dollars)
1990 1991 1992 1993 1994 1995 1996
Argentina 8 927 14 823 13 216 23 686 33 410 29 408 59 669
Brazil 1 075 -2 544 3 099 1 077 -2 030 -1 485 -25 700
Uruguay -4 364 955 -5 393 -9 546 -15 291 -10 534 -21 045
Paraguay -6 444 -9 818 -11 686 -15 683 -16 919 -21 726 -27 397
Source: Prepared by the authors on the basis of data from the INTAL database.
TABLE 12
Zonal orientation index in the pharmaceutical sector
1990 1991 1992 1993 1994 1995 1996
Argentina 4.56 3.47 3.88 2.47 2.88 2.33 3.09
Brazil 1.90 2.05 1.96 1.78 2.31 3.87 3.84
Uruguay 0.72 4.29 2.49 2.00 1.43 2.68 1.52
Paraguay 0.17 3.03 1.77 2.21 3.00 0.29 0.41
Source: Prepared by the authors on the basis of data from the INTAL database.
IV
Static and dynamic effects of trade
openness, integration and changes in
regulations on the pharmaceutical sector
The pharmaceutical industry is going through a process
of profound change, both at the zonal and the
international level. The enterprises in this sector have
had to adapt to new ways of carrying out their scientific
and technological research processes, new systems of
regulation (based fundamentally on trade liberalization
and the elimination of price controls), new market
signals, and new patterns of relations with public and
private bodies. In other words, the regional integration
process (through MERCOSUR) has coincided with other
structural changes that have taken place in the area.
This faces us with the methodological difficulty of
identifying which of the aspects of the process of change
in the sector which we discussed earlier can be
attributed to the effects of regional integration and
which are due rather to the impact of the other
phenomena mentioned. In the following sections we
will try to answer this question with regard to both static
and dynamic effects.
16
 The fact that there is a positive zonal orientation in the case of
Argentina is due to the fact that most of that country’s primary-
sector exports go to the “rest of the world”. If, instead of taking
total exports as our reference point,  we used exports of
manufactures, the opposite result would be obtained, because
pharmaceutical exports depend more on the zonal market than
primary exports, but less than the average for manufactures.
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1. Analysis of the static effects
Static analyses of integration and openness processes
are generally aimed at determining to what extent those
processes reduce the static distortions induced by trade
protection. Such analyses tend to center on the
behaviour of imports and the extent to which they
displace inefficient domestic production, but they also
involve the evaluation of domestic price trends and their
effect on the well-being of consumers.
From that view of the behaviour of trade, there
can be no doubt that both trade openness and regional
integration have generated static benefits in the area.
The total imports of the three countries studied have
increased, proportionately, much more than their
respective levels of apparent consumption. This has
markedly increased the sectoral imbalance of the area
with the rest of the world and raised its import
coefficients (although these continue to be relatively
low). There has consequently been a gradual decline
in the index of revealed comparative advantages of
the zone compared with the rest of the world, affecting
each of the four countries of the area more or less
equally.
At the same time, the integration process has made
possible a notable increase in intrazonal trade. Both
imports and exports are over ten times greater than they
were at the end of the 1980s. The fact that imports from
outside the area have also increased, while levels of
production have grown much less, gives grounds for
assuming that there has been a considerable process of
creation of trade in the area.
The trade pattern of the area shows us that the bulk of
its imports continue to come from the developed countries,
while the increase in the latter’s exports to MERCOSUR have
turned it into their main export destination.
The increase in the area’s exports has been led by
Argentina, which has consolidated its position as export
leader of MERCOSUR and continues to be the only
country with a positive sectoral balance. In spite of the
strong progress made by Brazil as a market for
Argentina’s exports, however, this mainly benefits the
transnational corporations operating in the sector, since
the exports of the local-capital firms go rather to the
Uruguayan and Paraguayan markets.17 This is attributed
by Argentine firms to the regulatory asymmetries
between Argentina and Brazil and the fact that in order
to export to Brazil it is necessary to make heavy
investments to win a place for their brands in that
market.
In Brazil, too, the transnational corporations
occupy a leading place in exports. There, out of the ten
main enterprises exporting to MERCOSUR (which
account for some 70% of total exports), eight are
transnationals and two are in the “unclassified”
category, while none of the main national laboratories
figure among the largest exporters to the area. The
transnational corporations also figure among the main
MERCOSUR importers of products. A number of
transnational corporations act both as importers and
exporters of pharmaceutical products, reflecting an
intra-industry specialization strategy.
The intrazonal trade structure would appear to
reflect a specialization pattern marked by the export of
bulk medicines and the importation of retail medicines
by Uruguay, while there is intra-industry specialization
between Argentina and Brazil in retail medicines (with
a high proportion of antibiotics, hormones and enzymes,
anti-inflammatories, etc.).
To sum up, the increase in tariff preferences in
MERCOSUR has clearly given rise to faster growth of
intrazonal exports than of exports to the rest of the
world: a process in which the transnational corporations
have been the clear leaders. This has also been
accompanied by an upward trend in imports from the
rest of the world, however, though this gives no grounds
for inferring the existence of diversion of trade and has
led to a slight decline in the index of intra-industry trade
and an erratic tendency in the zonal orientation index
during the decade.
The local-capital enterprises of all the countries
studied complain that there are asymmetries in the
regulations which make it difficult to take advantage
of the existing comparative advantages or that there is
a danger of excessive penetration by imports. The
Argentine enterprises claim that the restrictions on
access to the registration of medicines in Brazil mean
that only the transnational corporations can benefit from
the expansion of exports to that country. The problem
is that local-capital Argentine firms must undergo
stringent quality controls of their plants and products,
which limits the entry of their products into the
neighbouring country. Brazilian firms, for their part,
claim that health control rules are looser in Argentina
because there are fewer requirements as regards the
licensing and quality control of medicines, and this
affects the competitiveness of Brazilian products.
Another static effect of the greater trade openness in
Argentina and Brazil has been a sharp increase in
17
 And also to other Latin American countries, especially those
where the local-capital laboratories have plants of their own.
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imports of pharmaceutical products, which has helped
to bring down the production costs of the
pharmaceutical industry considerably.
It is interesting to note that the apparent positive
static effects of the behaviour of trade flows are in sharp
contrast with the behaviour of domestic prices, since
the domestic prices of medicines in the three countries
studied kept on rising throughout the 1990s.
In the case of Argentina, in particular, unit sales
stagnated (and even went down slightly, depending on
the years compared), whereas average prices in dollars
registered a constant increase which amounted to 100%
between 1991 and 1997 and 240% if 1988 is taken as
the starting point (data from CAEME). This means that
consumers have been seriously prejudiced by the effects
of the various changes that have taken place in the
sector. This trend towards higher prices is compounded
by some special characteristics of the health market,
such as the differentiation between those who decide
the expenditure that must be made – the doctors – and
those who have to pay it, or the existence of more or
less generalized health insurance arrangements. These
characteristics tend to give rise to excessive use of
medicines and an inability to negotiate over their prices
by those who have to foot the bill (fundamentally the
consumers).
2. Dynamic effects of the integration process
As we saw in section III, the pharmaceutical sector of
the area is going through a far-reaching process of
change. This is giving rise to big changes in the ways
of developing, manufacturing and marketing medicines,
through modifications in the forms of conduct and
strategies of the companies and institutions of the sector.
As we shall see below, the strategies differ considerably,
depending on whether they involve local-capital firms
or subsidiaries of transnational corporations.
How far has the integration process influenced
these changes? Both in Argentina and in Brazil,
companies have attached less importance to integration
as a catalyst of change than to changes in the regulations
(maximum prices, trade openness, the law on patents)
and macroeconomic stabilization. We will now describe
some of the areas where the integration process might
have been expected to have dynamic positive effects.
a) The pressures of competition and conversion of the
sector
As we already noted, neither the integration process
nor greater openness have so far given rise to greater
pressure through competition on the domestic prices
of the MERCOSUR countries. This may be attributed to
the market structure of the sector, in which medicinal
specialities generally have captive markets due to the
brand name (thanks to powerful promotional
campaigns) and in some cases strong concentration of
distribution is also taking place. Moreover, in many
cases the importation of medicines is controlled by the
producer laboratories themselves, so that the capacity
of imports to discipline prices is severely limited.
Although no competitive pressure on domestic
prices has been observed in the area, however, there
are clear signs of a new situation in terms of competition
due to the important changes that have been made in
the regulations, especially as regards patent law. The
changes caused by this new situation are so profound
that there is reason to doubt the viability of the local-
capital laboratories, especially the smaller ones.
The entry into force of the regulations on patents
narrows the production horizons of local firms, since it
limits their possibilities of participating in the production
of the new products which are coming onto the market
and which are usually the most profitable ones.
In view of this situation, the options open to local
firms are to seek agreements with the transnational
corporations, concentrate increasingly on the market
for generic drugs, or simply sell their plants.
The strategies of the larger firms seem to be
increasingly aimed at securing new kinds of strategic
alliances with the transnational corporations which
would allow them to gain early access to production
licences through joint marketing agreements or to act
as local distributors of the molecules and active
principles developed by those corporations abroad.
In order to improve their bargaining capacity with
foreign companies, one of the strategies which is being
increasingly used by the local laboratories of various
countries is to strengthen their marketing structures and
build up the prestige of their brands and the level of
confidence in them.
Greater participation in the market for generic
products is not an obvious solution for Argentine
companies. When an attempt was made there to impose
legislation to promote the use of those products, it was
seriously questioned by various sectors of the industry.
Since generic products require a modern industry and
high scales of production in order to keep costs down,
they have been developed to a greater extent in Brazil,
because of the large size of the local market.
This situation suggests that the tendency towards
increased participation by foreign companies in the
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markets of Brazil and Argentina will be further
strengthened in the future. The integration process has
increased the interest of the transnational corporations
in strengthening their position in those markets.
MERCOSUR offers them greater possibilities for
expanding intra-firm trade, because of the regional tariff
liberalization, the geographical proximity of the
markets, and the prospects that in the future a high level
of harmonization of regulations will be achieved among
the member countries. The most common strategy
adopted by those firms in Argentina, and especially in
Brazil, is to revitalize their production facilities, acquire
existing plants, and establish new distribution and
marketing networks.
In Uruguay, however, the opposite is taking place,
for the transnational corporations established in that
country are tending to give up local production and
sell only imported medicines, particularly from
Argentina. Some of the plants closed down by those
companies have been or are being bought by local firms
or “multilatins”: i.e., Latin American companies which
have operations in that country and in some other
MERCOSUR nation (Laens and Terra, 1998).
The repositioning of the transnational corporations
in Argentina and Brazil is taking place by various
means: some of them acquired companies which
previously belonged to local interests (Bristol-Myers
bought Argentia in Argentina) or merged with them
(Hanssen with Cilag Farma in Argentina; Merck, Sharp
and Dohme with Ache in Brazil), while some firms
which had lost dynamism during the 1980s recovered
their positions by rehabilitating and improving their
existing factories (Rhodia Farma in Brazil). Finally,
some firms opened new laboratories or embarked on
expansion projects involving the construction of
pharmaceutical plants (Bayer in Argentina; Glaxo
Wellcome and Pfizer in Brazil). This restructuring
process has also included the transfer of production
plants from one country to another, such as the closure
of plants in Uruguay and also in Argentina (Alcon) for
their relocation to Brazil.
Thus, except in Uruguay, over the last few years
market shares by capital origin have been changing in
the area in favour of the transnational laboratories. The
latter, however, show little or no interest in expanding
their capacity for the production of active principles or
pharmaceutical raw materials. Indeed, after the trade
openness process a number of transnational
corporations gave up producing active principles and
opted for a policy of managed intra-firm imports.
National firms too have been replacing the local
production of active principles with imports.18 This
process, which has enabled the laboratories to obtain a
reduction in the cost of their raw materials, has
considerably increased the trade deficit of the
pharmaceutical industry of the area.
b) Production specialization and reduction of the
range of products
The MERCOSUR integration process is accentuating a
trend arising from the globalization strategies of the
transnational corporations, which allow them to make
use of the advantages developed by the countries in
locating their different lines of medicines among them.
This enables them to reduce their range of products
and increase the production specialization of their
various subsidiaries, thus favouring a big increase in
intra-firm trading relations. As a result of this process,
for example, Glaxo has made its Argentine plants
specialize in antibiotics and its Brazilian ones in tablets
and creams, while Roche produces vitamins in its
Argentine plants and imports injectable products from
Brazil.
In the case of local-capital firms, the Argentine
laboratories interviewed are using two mechanisms in
order to reduce their product range. On the one hand,
they are reducing the amount of products they place on
the market, thus enabling them to concentrate their
research and marketing efforts. On the other hand, a
number of firms have established supply agreements
with other national firms for the mutual supply of
different types of products which they then sell under
their own brands, because of the need to increase their
competitiveness (through economies of scale), as well
as for health reasons (one laboratory cannot produce
different lines of medicines.
The local-capital laboratories of Uruguay are also
reducing their product ranges, giving up the production
of certain lines, which they have begun to import from
Argentina, and specializing in others in order to take
advantage of economies of scale and brands which are
common to both countries. In the case of Brazil, it is
the transnational laboratories which can benefit by
relocating their production activities among the
MERCOSUR countries.
18
 This is not the case in Uruguay, which has not developed the
production of active principles, so that the pharmaceutical firms of
that country, which no longer see the area as a source of supply of
raw materials, are calling for a reduction on the common external
tariff levied on them.
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c) Export strategies and regional business alliances
As already noted, MERCOSUR has favoured trade
relations among transnational corporations in the area,
giving rise to the expansion of intra-firm trade. Only in
a few cases has there been an increase in trade between
Argentina and Brazil due to the exports of local firms.
The Argentine firms claim that this is very difficult
because of the restrictions on the certification of
products in the Brazilian register and the need to make
heavy investments in marketing. In this respect, the
impact of area integration on strategic export-based
development has been felt above all in the case of
exports to the smaller countries of the area. This is
particularly noteworthy in the case of locally-owned
enterprises which have plants in Argentina and Brazil,
such as Elea, Bagó and Raffo. Some of the local firms
interviewed say that such exports to MERCOSUR have
enabled them to carry out a learning process with regard
to export activities.
According to the transnational corporations located
in Brazil which were interviewed, MERCOSUR has not
significantly altered their behaviour in the markets of
the area because their business strategies are based to a
much larger extent on their relations with their head
offices. Brazilian local-capital firms, however, display
defensive strategies with respect to MERCOSUR, which
they attribute to the fact that they consider it a market
with little growth potential, but which may in fact be
connected with their lower competitiveness compared
with the Argentine plants.
The restrictions referred to by the local-capital firms
of the MERCOSUR countries mean that in order to expand
their trade in the area they need a local partner in one of
the other countries of the bloc. So far, practically no trade
or production agreements have been made between local-
capital firms of Argentina and Brazil. From the point of
view of the Argentine firms, the possibilities of
association are limited because of the relative weakness
of the Brazilian firms, while the latter, as already noted,
take a defensive stance which they attribute to the
unfavourable asymmetry of the regulations.
In both countries, however, there have been trade
agreements led by companies which have made
technological advances of their own.19
d) Development of technological capacity, capture of
certain market niches, and strengthening of
marketing structures
The fundamental research of the transnational
corporations is concentrated outside the region. While
innovation is part of the world strategy for those
companies, at the local level it seems to be directed
more towards organizational changes, especially in
business management and marketing.
Some local-capital Argentine laboratories are
carrying out applied research, and for this purpose they
have signed collaboration agreements with universities
and research centres, aided by the loans made by the
Fondo Tecnológico Argentino. In a few cases, these
agreements have enabled them, as already noted earlier,
to make technological advances of their own, especially
in the field of biotechnological products. The levels of
investment in scientific and technological research are
low, however, and it is not possible to advance beyond
a certain point because of the high cost of securing
registration in the countries of the north.
Other local-capital Argentine firms are carrying out
product differentiation processes with regard to both
the characteristics of medicines and their packaging.
In other cases, they have tended to engage in production
for certain market niches, such as natural plant-based
medicinal products, which are not patentable. The
impression which emerges from the interviews,
however, is that, because of their lower level of scientific
and technological maturity, except in a few cases the
local-capital firms have opted to give up their previous
in-house scientific and technological research efforts.
The strategies of the Argentine and Brazilian local-
capital firms appear to be highly conditioned by the
economic openness process and the patents law, which
imposes limitations regarding the launching of new
products which will come into effect immediately (for
Brazilian firms) or in the near future (for Argentine
companies). This augurs future setbacks in their
respective domestic market shares.
e) Some pending issues in the integration process
It may be concluded from this study that the MERCOSUR
integration process in the pharmaceutical products
sector is still at a very incipient stage, in that the
19
 In Brazil, the Macrobiológica company (which has made
advances in the production of active principles) signed a trade
agreement with an Argentine firm to sell raw materials to the latter,
while in Argentina the Bio Sidus company (which has made
advances of its own in the field of biotechnology) has also made a
trade agreement with a Brazilian firm, in open competition with
transnational corporations, which has made it the fifth largest exporter
of pharmaceutical products to Brazil and enabled it to increase its
shares of both the Brazilian and the Latin American markets.
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liberalization of trade in this field among the countries
of the area is still far from being sufficient to form an
integrated market. Among the tasks which are still
outstanding in order to achieve this objective and
strengthen the development of dynamic comparative
advantages over third countries, mention may be made
of the following:
i) Elimination of asymmetries in regulations. This
involves a broad range of policies and actions of
the national public health bodies, such as
harmonization of the rules on product licensing and
the certification of bio-equivalent products, the
health standards needed for the importation of
medicines, regulations on the marketing of generic
products, etc. It also includes the harmonization
of policies which are the responsibility of other
public bodies, such as those on patent law and
policies on competition in the marketing of
products.
ii) Promotion of technological cooperation agreements
in order to further the area’s development in this
field. An example of action taken in this field is the
Argentine-Brazilian Biotechnology Agreement
(CABIO), adopted in 1986. Indeed, a number of
studies suggest that priority should be given to the
technological efforts of the countries of the periphery
in the areas of biotechnology and fine chemicals,
since they cover a wide field and could be applied
in a relatively short space of time. CABIO registered
only limited success, but this does not mean that
strategies to promote technological agreements at
the zonal level should be abandoned. The present
study bears witness to the different performance in
terms of trade and business dynamism displayed by
firms which have made technological innovations
of their own.
iii)  Reduction of the obstacles to competition
represented by captive brand-name markets,
through a faster transition towards the
consumption of generic products (Katz, 1997). This
process is making most progress in Brazil. At the
national level, it will make it possible to advance
in the deregulation of the pharmaceutical products
market, while minimizing the negative impact of
this process on the well-being of consumers. At
the zonal level, it will increase the capacity of local-
capital laboratories to compete in their countries’
markets. One of the most serious problems in this
connection is the lack of information of doctors
and consumers regarding the quality of generic
products. Coordination among the countries of the
area could help to increase their capabilities both
as regards past experience and legislation to
facilitate this transition and as regards all aspects
of the certification of bio-equivalent products.
(Original: Spanish)
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